Billionaire Ken Griffin's Citadel Returned a Whopping $7 Billion to Investors -- These Are 3 of Its Biggest HoldingsThe Motley Fool • 12/14/23
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion DealSeeking Alpha • 11/12/23
Boston Scientific Inches Closer To A Breakout After Eking Out A Third-Quarter BeatInvestors Business Daily • 10/26/23
Boston Scientific beats quarterly profit estimates on strength in heart devices unitReuters • 10/26/23
Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE TrialPRNewsWire • 10/25/23
REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary EmbolismPRNewsWire • 10/24/23